Can systemic immune inflammation index at admission predict in-hospital mortality in chronic kidney disease patients with SARS-CoV-2 infection? Arzu Ozdemir, Sibel Yucel Kocak, Semsi Nur Karabela, Mürvet Yılmaz

Effectivity and safety profile of tenapanor, a sodium-hydrogen exchanger isoform 3 inhibitor, as an innovative treatment for hyperphosphatemia in chronic kidney disease: A systematic review of clinical studies William Suciangto, Haerani Rasyid, Anastasya Angelica Vicente, Winny Suciangto

Telomerase activity in patients with stage 2–5D chronic kidney disease Veysel Kidir, Ayse Aynali, Atila Altuntas, Salih Inal, Buket Aridogan, Mehmet Tugrul Sezer